ProCE Banner Activity

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Slideset

Slides from a live webinar covering the mechanism of action, current approved indications, and adverse event management in patients receiving anti-CD3xCD20 bispecific antibody therapy for relapsed/refractory DLBCL

Released: September 25, 2024

Expiration: September 24, 2025

Share

Faculty

Sherry Adkins

Sherry Adkins, MSN, ANP-C, FAAN

Advanced Practice Provider
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Clinical Care Options, LLC and Practicing Clinicians Exchange (PCE)

ProCE Banner

Supporters

Supported by an educational grant from Genmab US, Inc.

Genmab US, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner